Vimarsana
Biggest News Aggregation in the World

Med Sci News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Med Sci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Med Sci Today - Breaking & Trending Today

Diagnosis of Crohn's Disease Linked to Chronic Kidney Disease Risk - Vimarsana News

Diagnosis of Crohn's Disease Linked to Chronic Kidney Disease Risk

A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

As Allergy Season Approaches, What Does the Future of Treatment Look Like for Chronic Rhinosinusitis? - Vimarsana News

As Allergy Season Approaches, What Does the Future of Treatment Look Like for Chronic Rhinosinusitis?

For patients with chronic rhinosinusitis, seasonal allergies may only make the condition worse.

Best Bladder-Friendly Drinks for Managing Urinary Incontinence - Vimarsana News

Best Bladder-Friendly Drinks for Managing Urinary Incontinence

Discover the best and worst drinks for managing urinary incontinence, empowering better choices for a healthier and more comfortable life.

TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer - Vimarsana News

TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer

Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, […]

GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseasesOn track to launch a Phase 2a biomark...